CASI Pharmaceuticals Inc (CASI) - Net Assets
Based on the latest financial reports, CASI Pharmaceuticals Inc (CASI) has net assets worth $-28.59 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.46 Million) and total liabilities ($53.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CASI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.59 Million |
| % of Total Assets | -116.88% |
| Annual Growth Rate | 7.7% |
| 5-Year Change | -98.21% |
| 10-Year Change | N/A |
| Growth Volatility | 397.12 |
CASI Pharmaceuticals Inc - Net Assets Trend (1994–2024)
This chart illustrates how CASI Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore CASI total asset value for the complete picture of this company's asset base.
Annual Net Assets for CASI Pharmaceuticals Inc (1994–2024)
The table below shows the annual net assets of CASI Pharmaceuticals Inc from 1994 to 2024. For live valuation and market cap data, see CASI Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.85 Million | -92.34% |
| 2023-12-31 | $24.16 Million | -63.90% |
| 2022-12-31 | $66.93 Million | -38.00% |
| 2021-12-31 | $107.96 Million | +4.23% |
| 2020-12-31 | $103.57 Million | +10.58% |
| 2019-12-31 | $93.67 Million | -14.43% |
| 2018-12-31 | $109.46 Million | +184.02% |
| 2017-12-31 | $38.54 Million | +85.43% |
| 2016-12-31 | $20.78 Million | +441.42% |
| 2015-12-31 | $-6.09 Million | -1341.80% |
| 2014-12-31 | $-422.21K | -102.83% |
| 2013-12-31 | $14.94 Million | +81.44% |
| 2012-12-31 | $8.24 Million | +225.28% |
| 2011-12-31 | $2.53 Million | -52.53% |
| 2010-12-31 | $5.33 Million | +376.92% |
| 2009-12-31 | $-1.93 Million | -132.52% |
| 2008-12-31 | $5.92 Million | -77.98% |
| 2007-12-31 | $26.90 Million | -42.75% |
| 2006-12-31 | $46.98 Million | +59.87% |
| 2005-12-31 | $29.39 Million | -17.74% |
| 2004-12-31 | $35.72 Million | +2.43% |
| 2003-12-31 | $34.88 Million | +231.81% |
| 2002-12-31 | $10.51 Million | -54.72% |
| 2001-12-31 | $23.21 Million | +21.80% |
| 2000-12-31 | $19.06 Million | -13.37% |
| 1999-12-31 | $22.00 Million | -33.73% |
| 1998-12-31 | $33.20 Million | -21.14% |
| 1997-12-31 | $42.10 Million | -11.74% |
| 1996-12-31 | $47.70 Million | +1225.00% |
| 1995-12-31 | $3.60 Million | +1700.00% |
| 1994-12-31 | $200.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CASI Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68727500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.11% |
| Other Comprehensive Income | $-1.77 Million | -95.84% |
| Other Components | $703.70 Million | 38017.18% |
| Total Equity | $1.85 Million | 100.00% |
CASI Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of CASI Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vault Strategic Mining Corp.
V:KNOX
|
$4.27 Million |
|
NEX Metals Exploration Ltd
AU:NME
|
$4.27 Million |
|
Nagreeka Capital & Infrastructure Limited
NSE:NAGREEKCAP
|
$4.27 Million |
|
NedSense Enterprises NV
AS:NEDSE
|
$4.27 Million |
|
Horus AG
STU:HRU
|
$4.26 Million |
|
Alliance Pharma plc
LSE:APH
|
$4.26 Million |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
$4.25 Million |
|
Yunnan Water Investment Co. Limited
F:2WI
|
$4.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CASI Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 24,165,000 to 1,851,000, a change of -22,314,000 (-92.3%).
- Net loss of 39,258,000 reduced equity.
- Dividend payments of 718,000 reduced retained earnings.
- New share issuances of 15,000,000 increased equity.
- Other comprehensive income decreased equity by 574,000.
- Other factors increased equity by 3,236,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.26 Million | -2120.91% |
| Dividends Paid | $718.00K | -38.79% |
| Share Issuances | $15.00 Million | +810.37% |
| Other Comprehensive Income | $-574.00K | -31.01% |
| Other Changes | $3.24 Million | +174.82% |
| Total Change | $- | -92.34% |
Book Value vs Market Value Analysis
This analysis compares CASI Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.68x to 2.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $0.36 | $0.24 | x |
| 1995-12-31 | $7.20 | $0.24 | x |
| 1996-12-31 | $535.63 | $0.24 | x |
| 1997-12-31 | $383.81 | $0.24 | x |
| 1998-12-31 | $287.97 | $0.24 | x |
| 1999-12-31 | $175.35 | $0.24 | x |
| 2000-12-31 | $130.43 | $0.24 | x |
| 2001-12-31 | $141.02 | $0.24 | x |
| 2002-12-31 | $52.73 | $0.24 | x |
| 2003-12-31 | $128.06 | $0.24 | x |
| 2004-12-31 | $105.66 | $0.24 | x |
| 2005-12-31 | $67.06 | $0.24 | x |
| 2006-12-31 | $71.88 | $0.24 | x |
| 2007-12-31 | $35.15 | $0.24 | x |
| 2008-12-31 | $7.53 | $0.24 | x |
| 2009-12-31 | $-2.41 | $0.24 | x |
| 2010-12-31 | $5.51 | $0.24 | x |
| 2011-12-31 | $2.15 | $0.24 | x |
| 2012-12-31 | $4.32 | $0.24 | x |
| 2013-12-31 | $5.72 | $0.24 | x |
| 2014-12-31 | $-0.15 | $0.24 | x |
| 2015-12-31 | $-1.88 | $0.24 | x |
| 2016-12-31 | $3.72 | $0.24 | x |
| 2017-12-31 | $6.27 | $0.24 | x |
| 2018-12-31 | $12.92 | $0.24 | x |
| 2019-12-31 | $7.61 | $0.24 | x |
| 2020-12-31 | $7.38 | $0.24 | x |
| 2021-12-31 | $6.21 | $0.24 | x |
| 2022-12-31 | $3.27 | $0.24 | x |
| 2023-12-31 | $1.81 | $0.24 | x |
| 2024-12-31 | $0.12 | $0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CASI Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2120.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -137.57%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 29.00x
- Recent ROE (-2120.91%) is below the historical average (-220.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -1706.67% | -5688.89% | 0.11x | 2.67x | $-5.15 Million |
| 1995 | -214.17% | -1070.83% | 0.07x | 2.81x | $-8.07 Million |
| 1996 | -10.06% | -109.09% | 0.08x | 1.13x | $-9.57 Million |
| 1997 | -15.48% | -135.42% | 0.10x | 1.14x | $-10.70 Million |
| 1998 | -40.66% | -259.62% | 0.13x | 1.19x | $-16.82 Million |
| 1999 | -167.73% | -738.00% | 0.16x | 1.45x | $-39.10 Million |
| 2000 | -256.27% | -1328.90% | 0.12x | 1.65x | $-50.70 Million |
| 2001 | -186.72% | -2326.02% | 0.04x | 1.99x | $-45.63 Million |
| 2002 | -371.86% | -3316.83% | 0.04x | 2.65x | $-40.07 Million |
| 2003 | -55.92% | -1237.29% | 0.04x | 1.15x | $-22.98 Million |
| 2004 | -35.35% | -2455.65% | 0.01x | 1.10x | $-16.19 Million |
| 2005 | -55.55% | -275.65% | 0.16x | 1.24x | $-19.25 Million |
| 2006 | -106.23% | -723.62% | 0.12x | 1.19x | $-54.59 Million |
| 2007 | -83.32% | -303.03% | 0.14x | 1.97x | $-25.10 Million |
| 2008 | -402.93% | -319.13% | 0.26x | 4.88x | $-24.45 Million |
| 2009 | 0.00% | -155.49% | 0.52x | 0.00x | $-8.02 Million |
| 2010 | -151.89% | -219.35% | 0.46x | 1.51x | $-8.63 Million |
| 2011 | -180.05% | -234.87% | 0.60x | 1.28x | $-4.81 Million |
| 2012 | -176.62% | -2173.17% | 0.07x | 1.09x | $-15.37 Million |
| 2013 | -38.40% | 0.00% | 0.00x | 1.04x | $-7.23 Million |
| 2014 | 0.00% | -110432.45% | 0.00x | 0.00x | $-26.16 Million |
| 2015 | 0.00% | -15104.01% | 0.01x | 0.00x | $-6.60 Million |
| 2016 | -45.48% | 0.00% | 0.00x | 1.33x | $-11.53 Million |
| 2017 | -27.95% | 0.00% | 0.00x | 1.17x | $-14.62 Million |
| 2018 | -25.10% | 0.00% | 0.00x | 1.04x | $-38.42 Million |
| 2019 | -62.14% | -1098.09% | 0.04x | 1.41x | $-52.66 Million |
| 2020 | -59.22% | -318.92% | 0.12x | 1.57x | $-56.44 Million |
| 2021 | -43.38% | -121.50% | 0.22x | 1.64x | $-45.10 Million |
| 2022 | -92.01% | -95.14% | 0.45x | 2.16x | $-45.47 Million |
| 2023 | -111.48% | -79.51% | 0.45x | 3.11x | $-29.35 Million |
| 2024 | -2120.91% | -137.57% | 0.53x | 29.00x | $-39.44 Million |
Industry Comparison
This section compares CASI Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CASI Pharmaceuticals Inc (CASI) | $-28.59 Million | -1706.67% | N/A | $4.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more